

REMARKS

In view of the above amendments and the following remarks, reconsideration of the outstanding office action is respectfully requested.

Claims 89-110, 112, and 149-153 are pending. Claim 89 has been amended and claims 111 and 148 have been canceled. Support for the amendments to claim 89 is found on page 7, lines 23-25; page 23, line 40 to page 24, line 2; and page 43, lines 22-24. No new matter has been added.

The United States Patent and Trademark Office ("PTO") has taken the position that the pending claims of present application are not entitled to claim priority to U.S. Provisional Application Serial No. 60/011,359 ("359 application"), filed February 9, 1996, because the recited feature of "selecting multimer nucleotides with nucleotide sequences differing from each other by at least 2 nucleotides..." is not supported in the '359 application. Applicants respectfully disagree.

The '359 application is replete with teachings that multimer nucleotides (e.g. tetramers) having nucleotide sequences that differ from each other by at least 2 nucleotides are selected. *See* pg. 40, lines 24-28; pg. 41, lines 10-11; pg. 41, line 13 to pg. 42, line 1; pg. 44, lines 19-21; and pg. 45, lines 32-34 of the '359 application. Therefore, the recited feature, "selecting multimer nucleotides with nucleotide sequences differing from each other by at least 2 nucleotides . . ." is fully supported by the disclosure of the '359 application.

Because the '359 application more than adequately supports the pending claims, applicants respectfully submit that the present application is entitled to the benefit of the earlier filing date of the '359 application.

Applicants submit that citation no. 1 listed under Non-Patent Literature on the IDS filed on November 8, 2007, ("Biocompare") was originally cited on a PTO-892 form by the PTO during the prosecution of related U.S. Patent Application Serial No. 10/272,152 on March 1, 2007 (please see attached PTO-892 form and copy of reference as provided by the PTO). Neither the PTO-892 form nor the copy of the reference supplied by the PTO provided a date of first publication or availability. Therefore, applicants are unable to provide this publication information. Nevertheless, it is respectfully requested that the PTO consider this reference just like it was considered previously.

The objection to claim 89 for missing the word "the" is respectfully traversed in view of the amendment above.

The rejection of claims 89-97, 109, 111-112, 148-151, and 153 under 35 U.S.C. § 112 (first para.) for failure to comply with the written description requirement is respectfully traversed.

The PTO asserts that claim 89 is drawn to a genus of multimer nucleotides that can be used to form a genus of capture oligonucleotides, and neither the specification nor the claims have demonstrated a common structure and/or function for the claimed genus of oligonucleotides. Applicants respectfully disagree.

Firstly, claim 89 is drawn to a method of forming arrays of oligonucleotides rather than oligonucleotides per se. The claimed method further involves forming oligonucleotides on an array from one or more multimer units where the selected multimer units have nucleotide sequences that differ from each other by at least 2 nucleotides. Additionally, no two dimers in a multimer are complementary to each other and the multimers do not undergo self-pairing or hairpin formation. An example of assembling arrays using multimers (e.g. tetramers) that meet these criteria is provided in the present application starting at page 38, line 20. Of the 256 (4^4) possible ways in which four bases can be arranged as tetramers, 36 tetramers meet the recited claim limitations (see Table 1 of the present application). The genus of capture oligonucleotides that are formed by the method of the present invention, therefore, are sufficiently described based on their selective multimer unit building block composition.

Further, applicants submit that claim 89 has been amended to recite that each capture oligonucleotide formed from the plurality of the multimer nucleotides has greater than sixteen nucleotides and each capture oligonucleotide of the array differs in sequence from its adjacent capture oligonucleotide, when aligned to each other by at least 25% of the nucleotides. These additional limitations further defined and limit the genus of oligonucleotides formed using the method of the present invention.

Therefore, because each capture oligonucleotide produced according to the method of the present invention is formed from a select, well-defined genus of multimer units, has greater than sixteen nucleotides, and differs in sequence from its adjacent capture oligonucleotide, when aligned by at least 25% of the nucleotides, the requirements of 35 U.S.C. § 112 (first para.) have been satisfied and this rejection should be withdrawn.

The rejection of claims 89-97, 109, 111, 112, and 148-153 under 35 U.S.C. § 112 (second para.) for indefiniteness is respectfully traversed.

The PTO asserts that the limitation “selecting multimer nucleotides with nucleotide sequences differing from each other by at least 2 nucleotides, wherein no two dimers in the multimers are complementary to each other” is indefinite. Specifically, the PTO states that

where the multimers are the tetramers shown in Table 1 of the specification, some tetramers do not differ by at least two nucleotides.

Applicants submit that the above recited phrase of claim 89 is not indefinite. The limitation explicitly recites that “multimer nucleotides with nucleotide *sequences* differing from each other by at least 2 nucleotides . . .” (emphasis added). As defined by the Oxford English Dictionary, “sequence” refers to “the *order* of the constituent nucleotides in a nucleic acid molecule or of the amino-acids in a polypeptide or protein molecule” (emphasis added) (see Oxford English Dictionary Online entry I. 2. c. for “sequence” attached hereto as Exhibit 1). Accordingly, the sequence of the constituent nucleotides of each tetramer in Table 1, from amino to carboxy terminus, differs from the sequence of nucleotides in all other tetramers by at least 2 nucleotides as recited in claim 89.

In view of the forgoing, applicants respectfully request that the rejection of claims 89-97, 109, 111, 112, and 148-153 for indefiniteness be withdrawn.

The rejection of claims 89-97, 109, 111-112, and 148-153 under 35 U.S.C. § 103 for obviousness over U.S. Patent No. 5,510,270 to Fodor et al. (“Fodor”) in view of U.S. Patent No. 5,474,796 to Brennan et al. (“Brennan”) and U.S. Patent No. 5,594,121 to Froehler et al. (“Froehler”) is respectfully traversed.

Fodor relates to a method for synthesizing and screening polymers on a solid substrate. The method includes providing a substrate which may include linker molecules on its surface. On the substrate or a distal end of the linker molecules, a functional group with a protective group is provided. The protective group may be removed upon exposure to radiation, electric fields, electric currents, or other activators to expose the functional group. Using photolithographic methods, the protective group is removed in first selected regions and the substrate is contacted with a first monomer which reacts with the functional group. Thereafter, second selected regions are deprotected and exposed to a second monomer which reacts with the exposed functional group. These steps are repeated until the substrate includes desired polymers of desired lengths. Monomers may include amino acids, nucleotides, pentoses, and hexoses.

Brennan relates to an apparatus and methods for making arrays having functionalized binding sites on a support surface and conducting oligonucleotide synthesis at such sites on the surface. Brennan further relates to a method of determining or confirming the nucleotide sequence of a target nucleic acid where the target nucleic acid is labeled and hybridized to oligonucleotides of known sequence bound to sites on the array plate.

Froehler discloses novel oligomers containing 7-deaza-7-substituted purines and related analogs that have enhanced ability for double-and triple-helix formation with single- or double-stranded target nucleic acid sequences. Such oligomer analog compositions can be used for diagnostic assays that employ methods where the oligomer or nucleic acid to be detected is covalently attached to a solid support.

The PTO acknowledges that Fodor fails to teach attaching “multimer nucleotides” to the array surface where each multimer has a nucleotide sequence that differs from all other multimers by at least 2 nucleotides and where no two dimers in a multimer are complementary to each other. Fodor also fails to suggest that the multimers would not result in self-pairing or hairpin formation. However, the PTO asserts that Brennan and Froehler teach these limitations. Applicants respectfully disagree.

Brennan teaches arrays of trimer and 10-mer oligonucleotides. Synthesis of these oligonucleotides is carried out such that each oligonucleotide element, moving in a 5' to 3' direction, is identical to the preceding oligonucleotide element in nucleotide sequence, except that the most 5' nucleotide is deleted and a new nucleotide is added at the 3' end (See col. 9, second full paragraph). Although the synthesis method of Brennan produces all permutations of a trimer or 10-mer sequence, Brennan fails to exclude the use of trimers or 10-mers which contain complementary dimers or which do not undergo self pairing or hairpin formation. In addition, Brennan fails to teach trimer or 10-mer capture oligonucleotides where each capture oligonucleotide of the array differs in sequence from its adjacent capture oligonucleotide, when aligned to each other by at least 25% of the nucleotides. In fact, following the method of oligonucleotide synthesis taught by Brennan, each “oligonucleotide element, moving in a 5'-3' direction, is identical to the preceding element in nucleotide sequence except that it deletes the 5'-most nucleotide and adds a 3'-most oligonucleotide.” Therefore, adjacent oligonucleotides formed according to the method of Brennan will have significant similarity when aligned. In other words, because nine out of ten nucleotides of adjacent 10mers are similar, adjacent 10mers have 90% sequence identity when aligned, differing by only 10% (see ClustalW2 pairwise sequence alignment results attached hereto as Exhibit 2).

Froehler, while teaching that oligomers (e.g. dimers – hexamers) are useful as synthons (i.e. structural unit within a unit) for producing longer oligomers, fails to teach that the synthons must not contain complementary dimers and must not undergo self pairing or hairpin formation. In addition, Froehler fails to teach oligomers on a solid support where each oligomer differs in sequence from its adjacent oligomer, when aligned to each other by at least 25% of the nucleotides.

Applicants submit that the combination of Fodor, Brennan, and Froehler fails to teach a method of producing oligonucleotides using multimer units, where the multimer units do not contain complementary dimers and do not undergo self pairing or hairpin formation, and where each capture oligonucleotide differs in sequence from its adjacent capture oligonucleotide, when aligned to each other by at least 25%. Further, this combination of references fails to teach a method where such capture oligonucleotides are attached to a solid support and hybridize to complementary oligonucleotide target sequences under *uniform* hybridization conditions across the array of oligonucleotides.

Since the combination of the Fodor, Brennan, and Froehler fails to teach the claimed invention, the rejection of claims 89-97, 109, 111-112, and 148-153 based on these references is improper and should be withdrawn.

The rejection of claims 89-94, 96-97, 109, 111-112, and 148-153 under 35 U.S.C. § 103(a) for obviousness over U.S. Patent No. 5,527,681 to Holmes ("Holmes") in view of Brennan and Froehler is respectfully traversed.

Holmes relates to methods, devices, and compositions for synthesis and use of diverse molecular sequences on a substrate. In particular, Holmes discloses the synthesis of an array of polymers in which individual monomers in a lead polymer are systematically substituted with monomers from one or more basic sets of monomers. On the substrate or a distal end of linker molecules, a functional group with a protective group is provided. The protective group may be removed upon exposure to a chemical reagent, radiation, electric fields, electric currents, or other activators to expose the functional group. Using photolithographic methods, the protective group is removed in first selected regions and the substrate is contacted with a first monomer which reacts with the functional group. Thereafter, second selected regions are deprotected and exposed to a second monomer which reacts with the exposed functional group. These steps are repeated until the substrate includes desired polymers of desired lengths. Monomers may include amino acids, nucleotides, pentoses, and hexoses.

The PTO acknowledges that Holmes does not teach attaching multimer nucleotides to the array surface where each multimer has a nucleotide sequence that differs from all other multimers by at least 2 nucleotides and where no two dimers in a multimer are complementary to each other. Holmes also fails to teach that the multimers would not result in self-pairing or hairpin formation. However, the PTO asserts that Brennan and Froehler teach these limitations. Applicants respectfully disagree for the same reasons as set forth above.

Accordingly, the rejection of claims 89-94, 96-97, 109, 111-112, and 148-153 under 35 U.S.C. § 103(a) for obviousness over Holmes in view of Brennan and Froehler is improper and should be withdrawn.

The rejection of claims 89 and 149-151 under the judicially-created doctrine of obviousness-type double patenting over claims 1 and 2 of U.S. Patent Application Serial No. 10/257,158, now U.S. Patent No. 7,455,965 ("965 patent"), is respectfully traversed.

The '965 patent relates to a method of designing a plurality of capture oligonucleotide probes for use on a support, to which complementary oligonucleotide probes will hybridize. This method involves providing a first set of tetramers, forming a collection of multimer units from the chosen tetramers, and then removing multimer units to form a modified collection of multimer units. The modified collection of multimers are randomized, divided into first and second sub-collections, and arranged according to melting temperature. Multimers of the first sub-collection are then linked to multimers of the inverted second sub-collection to form a collection of double multimer units which is subsequently further manipulated to produce a modified collection of double multimer units. This is patentably distinct from the present invention, which claims a method of forming arrays of oligonucleotides on a solid support. The claimed invention of the present application requires providing a solid support having an array of positions, each position suitable for attachment of an oligonucleotide. Claim 89 of the present application further requires attaching linkers to the solid support surface, where the linkers are suitable for coupling oligonucleotides to the solid support at each array position, activating the selected array positions for attachment of multimer nucleotides, and attaching the selected multimer nucleotides to the activated array positions. In view of the great difference between the claims of the present application and the claims of the '965 patent, the double patenting rejection based on the '965 patent is improper and should be withdrawn.

In view of the all of the foregoing, applicants submit that this case is in condition for allowance and such allowance is earnestly solicited.

Respectfully submitted,

Date: January 9, 2009

/Michael L. Goldman/
Michael L. Goldman
Registration No. 30,727

NIXON PEABODY LLP
1100 Clinton Square
Rochester, New York 14604-1792
Telephone: (585) 263-1304
Facsimile: (585) 263-1600

Notice of References Cited	Application/Control No. 10/272,152	Applicant(s)/Patent Under Reexamination BARANY ET AL.	
	Examiner Frank W. Lu	Art Unit 1634	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS


*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Rehman et al., Immobilization of acrylamide-modified oligonucleotides by co-polymerization. Nucleic Acids Research, 27, 649-655, published on January 15, 1999.
	V	Attachment for acrylamide.
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Attachment for Acrylamide




The Buyer's Guide for Life Scientists

Products | New Technologies | News | Promotions | Articles | Reviews | Videos/Slide Shows | Resources | Forums | Events

[Biocompare Home](#) > [Back](#) > [Technical Articles](#)

[Log In](#) | [Register](#) | [Advanced Search](#)



www.bio-rad.com/RNAi/

advertisement

Acrylamide Polymerization — A Practical Approach

Paul Menter, Bio-Rad Laboratories, 2000 Alfred Nobel Drive, Hercules, CA 94547 USA

Introduction

The unparalleled resolution and flexibility possible with polyacrylamide gel electrophoresis (PAGE) has led to its widespread use for the separation of proteins and nucleic acids. Gel porosity can be varied over a wide range to meet specific separation requirements. Electrophoresis gels and buffers can be chosen to provide separation on the basis of charge, size, or a combination of charge and size.

The key to mastering this powerful technique lies in the polymerization process itself. By understanding the important parameters, and following a few simple guidelines, the novice can become proficient and the experienced user can optimize separations even further.

This bulletin takes a practical approach to the preparation of polyacrylamide gels. Its purpose is to provide the information required to achieve reproducible, controllable polymerization. For those users interested only in the "bare essentials," the Polymerization Protocols can be used as a laboratory guide.


Mechanism of Polymerization

Polyacrylamide gels are formed by copolymerization of acrylamide and bis-acrylamide ("bis," N,N'-methylene-

bisacrylamide). The reaction is a vinyl addition polymerization initiated by a free radical-generating system (Chrambach 1985). Polymerization is initiated by ammonium persulfate and TEMED (tetramethylethylenediamine). TEMED accelerates the rate of formation of free radicals from persulfate and these in turn catalyze polymerization. The persulfate free radicals convert acrylamide monomers to free radicals which react with unactivated monomers to begin the polymerization chain reaction (Shi and Jackowski 1998). The elongating polymer chains are randomly crosslinked by bis, resulting in a gel with a characteristic porosity which depends on the polymerization conditions and monomer concentrations.

Riboflavin (or riboflavin-5'-phosphate) may also be used as a source of free radicals, often in combination with TEMED and ammonium persulfate. In the presence of light and oxygen, riboflavin is converted to its leuco form, which is active in initiating polymerization. This is usually referred to as photochemical polymerization.

Polyacrylamide Gel Polymerization



Purity of Gel-Forming Reagents

Acrylamide

Gel-forming reagents include the monomers, acrylamide and bis, as well as the initiators, usually ammonium persulfate and TEMED or, occasionally, riboflavin and TEMED. On a molar basis, acrylamide is by far the most abundant component in the monomer solution. As a result, acrylamide may be the primary source of interfering contaminants (Dirksen and Chrambach 1972). Poor-quality acrylamide contains significant amounts of the following contaminants:

1. Acrylic acid — Acrylic acid is the deamidation product of acrylamide. Acrylic acid will copolymerize with acrylamide

and bis, thereby conferring ion exchange properties on the resulting gel. This can lead to local pH changes in the gel and cause artifacts such as aberrant relative mobility, precipitation of some proteins and nucleic acids, streaking or smearing of bands, and run-to-run irreproducibility. In acrylamide, acrylic acid should be below 0.001% (w/w). This is determined by direct titration, and supported by both conductivity and pH measurement.

2. Linear polyacrylamide — Contaminants with catalytic properties may cause what appears to be autopolymerization during the production, processing, or storage of marginally pure acrylamide. This results in the presence of linear polyacrylamide in the dry monomer. Linear polyacrylamide will affect polymerization, since it serves as a nucleus for polymerization. The most important effect is the loss of reproducibility in gel porosity and relative mobilities of proteins and nucleic acids. Linear polyacrylamide is detected as water or alcohol insolubles and should be <0.005% (w/w).
3. Ionic contaminants — Ionic contaminants can include both inhibitors and accelerators of polymerization. Aside from acrylic acid, the most notable ionic contaminants are metals such as copper, which can inhibit gel polymerization. Metals can also poison enzymes, alter the relative mobility of metal binding proteins such as calmodulin, and inhibit digestion of electrophoretically purified nucleic acids by restriction and modification enzymes. Ionic contaminants are detected indirectly by their effects on chemical and photochemical polymerization, and by the conductivity of monomer solutions.

bis-Acrylamide

Bis is present in much smaller quantities than acrylamide in monomer solutions. However, improperly purified bis contains some of the same contaminants as acrylamide. These include products of autopolymerization and ionic contaminants, which have the same deleterious effects, and can be detected in the same ways, as the corresponding acrylamide contaminants.

Initiators

Chemical polymerization is initiated by ammonium persulfate, while photochemical polymerization is initiated by riboflavin (or riboflavin-5'-phosphate), or by a combination of riboflavin and ammonium persulfate. Initiation and polymerization are catalyzed by TEMED. Because polymerization is initiated by the generation of free radicals from persulfate or riboflavin, it is not surprising that these compounds are reactive, and prone to oxidation or decomposition. The contaminants of the initiators tend to be the products of their own breakdown as well as other contaminating compounds.

TEMED is subject to oxidation, which causes the gradual loss of catalytic activity. This process is greatly accelerated by contaminating oxidizing agents. TEMED that contains oxidation products is characterized by a yellow color. The practical consequences of the oxidative process are the requirement for greater amounts of TEMED to achieve

adequate polymerization, and a gradual loss of TEMED reactivity with time. TEMED is also very hygroscopic and will gradually accumulate water, which will accelerate oxidative decomposition. TEMED with maximum activity and shelf life is obtained by redistillation immediately prior to bottling, resulting in a product that is clear, water free, and greater than 99% pure (14.4 M).

Ammonium persulfate is also very hygroscopic. This property is particularly important, since ammonium persulfate begins to break down almost immediately when dissolved in water. Therefore, the accumulation of water in ammonium persulfate results in a rapid loss of reactivity. This is why ammonium persulfate solutions should be prepared fresh daily. Persulfate is consumed in the polymerization reaction. Excess persulfate can cause oxidation of proteins and nucleic acids. This oxidation problem can be avoided if inhibitor-free gel-forming reagents are used, and ammonium persulfate is used at the recommended levels.

Contaminants in Buffers

Contaminants in buffer reagents (Tris, borate, acetate, glycine, etc.), gel additives (SDS, urea, etc.), and laboratory water can have a profound effect on polymerization. The most common contaminants of these reagents are metals, non-buffer ions, and breakdown products. The most frequent effect of these contaminants is to inhibit polymerization. When polymerization is partially inhibited, the resulting gel will have greater porosity than intended, and molecules will have greater mobilities. Furthermore, control over polymerization reproducibility is compromised.

Initiator Type and Concentration

Initiators are the effectors of polymerization. Of course, the rate of polymerization depends on the concentration of initiators, but more importantly, the properties of the resulting gel also depend on the concentration of initiators. Increasing the concentration of initiators (e.g., ammonium persulfate and TEMED) results in a decrease in the average polymer chain length, an increase in gel turbidity, and a decrease in gel elasticity. In extreme cases, excess initiator can produce a gel solution that does not appear to polymerize at all. This is due to the formation of polymer chains so short that visible gelation does not take place and the polymer stays in solution. The only indication that a reaction has taken place is an increase in viscosity.

Excess ammonium persulfate and TEMED have other effects, including oxidation of sample proteins (especially sulfhydryl-containing compounds) and changes in buffer pH. Excess TEMED can increase buffer pH, react with proteins (Dirksen and Chrambach 1972; Chrambach *et al.* 1976), and alter the banding pattern (Gelfi and Righetti 1981a). Ammonium persulfate acts as a buffer between pH 8 and 9. Potassium persulfate is recommended instead of ammonium persulfate in weakly buffered basic systems (~pH 9). Excess riboflavin may cause the oxidation of some compounds, especially sulfhydryl-containing compounds (Dirksen and Chrambach 1972), and can denature proteins (Righetti *et al.* 1981).

Reducing the concentration of initiators results in longer polymer chain lengths, lower turbidity, and greater elasticity. These are desirable properties. However, lower initiator concentrations also mean slower polymerization. If polymerization is too slow, oxygen will begin to enter the monomer solution and inhibit polymerization, resulting in gels which are too porous and mechanically weak. Inhibition will be especially pronounced at surfaces exposed to air, or at the surfaces of combs and spacers, which appear to trap air at their surfaces. The remaining unpolymerized monomer can react with alpha amino, sulphydryl, and phenolic hydroxyl groups of proteins (Allison *et al.* 1974; Chrambach *et al.* 1976; Dirksen and Chrambach 1972).

For discontinuous systems which employ a stacking gel (e.g., Laemmli system), optimal polymerization of the overlaid lower gel (resolving gel) is achieved when visible gelation takes place 15–20 min after the addition of the initiators ammonium persulfate and TEMED (note that polymerization continues long after visible gelation takes place; see Figure 1). For stacking gels and continuous systems (which do not contain stacking gels) — i.e., any gel which is not overlaid — optimal polymerization results when visible gelation takes place in 8–10 min. Higher initiator concentrations and faster polymerization are required in these cases because of the inhibitory effect of atmospheric oxygen associated with the comb. In any case, conversion of monomer to polymer should be greater than 95%. If gelation takes longer than 20 min, the inhibitory effects of atmospheric oxygen will begin to appear.

As a general rule, use the lowest catalyst concentrations that will allow polymerization in the optimal period of time. In the case of ammonium persulfate/TEMED-catalyzed reactions, for example, approximately equimolar concentrations of both catalysts in the range of 1 to 10 mM are recommended.

Riboflavin is often used as an initiator along with TEMED, or with TEMED and ammonium persulfate. The major advantage of riboflavin is that it is active in very low concentrations (~5–10 µg/ml). Thus, when riboflavin is used with TEMED and ammonium persulfate, the total amount of initiator required (sum of the three initiators) is less. Given the possible effects of initiators on buffer pH, riboflavin-based initiator systems are useful for poorly buffered systems such as electrofocusing gels, in which the only buffering components are ampholytes.

Visible gelation takes longer in riboflavin-based initiator systems, usually 30–60 min. Oxygen does not have the dramatic inhibitory effect on riboflavin-based initiator systems that it has on TEMED/ammonium persulfate systems. This is presumably due to the oxygen-scavenging property of riboflavin. As a result, longer gelation time can be tolerated.

In chemical polymerization, visible gelation occurs in 15–20 min and polymerization is essentially complete in 90 min. In photochemical polymerization, however, visible gelation takes 30–60 min and complete polymerization requires up to 8 hr (Righetti *et al.* 1981). Shorter times lead to more porous and elastic gels, increased risk of protein modification,

and pore size irreproducibility.

Temperature

Temperature control is critical for reproducibility of acrylamide polymerization. Temperature has a direct effect on the rate of gel polymerization; the polymerization reaction is also exothermic. Consequently, the generated heat drives the reaction more quickly. Thus, gelation usually occurs very rapidly once polymerization begins.

Temperature also affects the properties of the gel (Chen and Chrambach 1979). For example, polymerization at 0–4°C results in turbid, porous, inelastic gels, and reproducibility is difficult to achieve. These properties may be due to increased hydrogen bonding of monomer at low temperatures. Gels polymerized at 25°C are more transparent, less porous, and more elastic. However, if the polymerization temperature is too high, short polymer chains are formed and the gels are inelastic. This is thought to be due to increased polymer chain termination at higher temperatures.

A temperature of 23–25°C is optimal (as well as most convenient) for polymerization. It is important that the monomer solution and the gel mold (e.g., glass plates or tubes) be at the optimal temperature when the gel is poured. Furthermore, reproducibility is dependent on using the same temperature each time gels are poured.

Since monomer solutions are usually stored at 4°C along with buffer concentrates, it is important to allow the monomer gel solution, once prepared, to equilibrate to room temperature before being evacuated (if cold solutions are placed under vacuum they tend to stay cold).

Oxygen

The formation of polyacrylamide gels proceeds via free radical polymerization. The reaction is therefore inhibited by any element or compound that serves as a free radical trap (Chrambach 1985). Oxygen is such an inhibitor. Oxygen, present in the air, dissolved in gel solutions, or adsorbed to the surfaces of plastic, rubber, etc., will inhibit, and in extreme cases prevent, acrylamide polymerization. Proper degassing is critical for reproducibility. Therefore, one of the most important steps in the preparation of polyacrylamide gels is the evacuation, or “degassing” of gel solutions immediately prior to pouring the gel. This is done by placing the flask of gel solution in a vacuum chamber or under a strong aspirator. In some cases, a vacuum pump may be required.

Buffer stock solutions and monomer stock solutions are usually stored at 4°C. Cold solutions have a greater capacity for dissolved oxygen. The process of degassing is faster and more complete if the gel solution is brought to room temperature (23–25°C), before degassing begins. Furthermore, if a cold gel solution is placed under vacuum, the process of evacuation tends to keep the solution cold. Pouring a gel with a cold solution will have a substantial negative effect on the rate of polymerization and on the quality of the resulting gel.

Polymerization in which riboflavin is used as one of the initiators calls for degassing. The conversion of riboflavin from the *flavo* to the *leuco* form (the species active in initiation) actually requires a small amount of oxygen (Gordon 1973).

This explains why polymerization initiated primarily by riboflavin can be completely blocked by exhaustive degassing. However, oxygen in excess of that needed to convert riboflavin to the active form will inhibit polymer chain elongation, as it does in reactions initiated only by ammonium persulfate and TEMED. Thus, while degassing is still important for limiting inhibition, it must not be so extensive that it prevents conversion of riboflavin to the active form. For polymerization initiated by riboflavin/TEMED, or riboflavin/TEMED/ammonium persulfate systems, degassing should not exceed 5 min.

A consequence of the interaction of riboflavin with oxygen is that riboflavin seems to act as an oxygen scavenger. This is supported by the observation that the addition of riboflavin (5 µg/ml) to stacking gel solutions containing ammonium persulfate/TEMED initiators results in cleaner, more uniform polymerization at gel surfaces exposed to oxygen (such as combs). The same effect could likely be achieved by more thorough degassing of solutions without riboflavin.

Whether using chemical polymerization (ammonium persulfate/TEMED) or photochemical polymerization (riboflavin/TEMED or riboflavin/TEMED/ammonium persulfate initiators), reproducible gel quality and separation characteristics require careful attention to gel solution temperature before degassing, and to degassing time, temperature, and vacuum. These parameters should be kept constant every time gels are prepared.

pH

The majority of electrophoresis systems are buffered at neutral or basic pH, at which the common initiators, ammonium persulfate, TEMED, and riboflavin, are effective. Riboflavin is the better choice for polymerization at low pH (Shi and Jackowski 1998); however, at low pH, TEMED may become protonated. This can result in slower polymerization, since the free base form of TEMED is required for initiation. For acidic buffer systems, alternative initiator systems are sometimes used (Andrews 1990).

Alternative Crosslinkers

PDA (piperazine di-acrylamide), a crosslinking agent that can be substituted for bis in polyacrylamide gels, offers several advantages for electrophoresis. These include reduced background for silver staining, increased gel strength, and higher-resolution gels. PDA can be substituted for bis on a weight basis without changing polymerization protocols.

Crosslinkers other than bis and PDA may be used for specialized purposes, the most common of which is gel

solubilization during post-electrophoresis recovery of proteins or nucleic acids. These crosslinkers include DATD (diallyltartardiamide), DHERA (dihydroxyethylene-bis-acrylamide), and BAC (bis-acrylylcystamine). Alternative crosslinkers may be more or less reactive in polymerization than bis. Therefore, some adjustment in the concentration of initiators may be necessary to achieve optimal polymerization. For a discussion of alternative crosslinkers, see Gelfi and Righetti (1981b).

Gel Additives

The most common gel additives include SDS (sodium dodecyl sulfate), Triton[®] X-100 detergent, and chaotropic agents such as urea and formamide. Detergents can be added to most common buffer systems without significantly affecting polymerization. Agents such as urea and formamide, however, cause the formation of smaller pore-size gels than would be formed in their absence (urea is often a component of gel systems used to separate small proteins and peptides). This may be due to the disruption of hydrogen bonds between monomer molecules during polymerization. Smaller pore size may also be achieved at higher polymerization temperatures, an effect also attributed to hydrogen bond disruption. Contaminants of gel additives can affect polymerization. Nonionic additives such as urea, formamide, and Triton X-100 can be deionized with a mixed-bed ion exchange resin. Use 10 gm Bio-Rad Ag 501 X-8 resin per 100 ml additive solution and let sit overnight. However, removal of nonionic contaminants from nonionic reagents is not practical. Therefore, all additives should be quality assured for electrophoresis.

Time

Although visible gelation occurs in 15–20 min for chemical polymerization and 30–60 min for photochemical polymerization, polymerization continues much longer (see Figure 1). Ammonium persulfate/TEMED-initiated reactions should be allowed to proceed for 2 hr to ensure maximum reproducibility in gel pore size. Photochemical polymerization (riboflavin-based initiator system) usually proceeds more slowly than chemical polymerization, and is also dependent on light intensity (Shi and Jackowski 1998). However, riboflavin is usually used for polymerization of electrofocusing gels in which separation is based on charge, and for which gel porosity is of secondary importance. Thus these gels can be used shortly after visible gelation without being affected by slight variations in porosity.

Monomer Concentration

The practical range for monomer concentration is between 3% T and 30% T, where %T refers to % (w/v) of total monomer (acrylamide + bis) in solution. A higher concentration of monomer results in faster polymerization. Therefore, changing from 5% gels to 30% gels will probably allow a reduction of 20–50% in the concentration of initiators.

Polymerization Protocols

There are 2 major initiator formulations for acrylamide polymerization. The first, for chemical polymerization, is used

for SDS-PAGE and DNA sequencing. Chemical polymerization employs ammonium persulfate and TEMED as initiators. The second, for photochemical polymerization, is used primarily for horizontal electrofocusing gels. Photochemical polymerization calls for riboflavin as well as ammonium persulfate and TEMED. Riboflavin phosphate can be substituted for riboflavin. Riboflavin phosphate is often preferred for its greater solubility.

Preparation for Polymerization

1. Prepare 10% ammonium persulfate shortly prior to use (prepare fresh daily). TEMED is used undiluted. Prepare 0.1% riboflavin (or riboflavin phosphate, which is more soluble) if photopolymerization will be performed.
2. Combine buffer stock solution, monomer stock solution, and water in the appropriate proportions in an Erlenmeyer flask. Since stock solutions are usually stored at 4°C, the gel solution should be allowed to warm to room temperature before degassing.
3. Prepare the gel casting mold, i.e., plates, spacers, and clamps for gel casting. Be sure they are neither hot nor cold.
4. Once the gel solution is prepared and brought to room temperature (23–25°C), degas the solution under a vacuum of 125 torr or better for 15 min at room temperature (for systems in which constant agitation is used during degassing, 10 min is sufficient). Longer periods of degassing are generally not deleterious, although long degassing will result in somewhat faster polymerization.

Chemical Polymerization in Discontinuous Systems — Lower (Resolving) Gel

In a discontinuous system, such as that of Laemmli, the resolving gel is polymerized first. Then, the stacking gel is cast on top of the resolving gel. Use the following protocol to prepare resolving gels for all discontinuous systems (see the next section for preparation of stacking gels).

Initiator volume per 10 ml gel solution		Initiator final concentration
Ammonium persulfate (10% w/v)	50 μ l	0.05%
TEMED (undiluted)	5 μ l	0.05%

Swirl the solution gently but thoroughly. Holding the flask by the neck with one hand, swirl it 8 to 10 cycles. This mixes

the initiators completely without introducing too much oxygen. Swirling too little can result in uneven polymerization.

Cast the gel by introducing the monomer solution into the gel mold in a steady stream to minimize the introduction of oxygen. Overlay the monomer solution using water, isoamyl alcohol, or water-saturated isobutyl alcohol to exclude oxygen from the surface.

Allow polymerization to occur at room temperature at least 90 min prior to use (see Figure 1).

Chemical Polymerization in Continuous Systems and Stacking Gels

Continuous systems consist of a single gel. Continuous systems are used for some types of protein electrophoresis, and for DNA sequencing. Stacking gels are part of discontinuous systems. These gels have in common contact with the well-forming comb and greater exposure to molecular oxygen at the surface. Use the following levels of initiators for continuous systems and stacking gels.

Ammonium persulfate (10% w/v)	Initiator volume per 10 ml gel solution		Initiator final concentration
	50 μ l	10 μ l	
TEMED (undiluted)			0.05%
			0.1%

Swirl the solution gently but thoroughly.

Cast the gel and insert the well-forming comb without trapping air under the teeth.

Allow polymerization to occur at room temperature at least 90 min prior to use (see Figure 1).

Photochemical Polymerization

This protocol is recommended for isoelectric focusing (IEF) gels. Since molecules remain in the IEF gel during electrophoresis, excess ions from initiators can cause distortion of bands. Photochemical initiation is recommended for IEF gels because it is effective at low initiator concentrations.

1. When the gel solution is prepared and brought to room temperature (23–25°C), degas the solution under a vacuum of 125 torr or better for 2 min at room temperature (for systems in which constant agitation is used for degassing, 1 min is sufficient).




Fig. 1. Polymerization profile for 12% monomer (12%T, 2.6%C) containing 0.375 M Tris-HCl, pH 8.8 (Lacmini), polymerized in a quartz cuvette at room temperature with ammonium persulfate and TEMED at final concentrations of 0.05% each. Polymerization was monitored at 260 nm. A, "enzyme grade" acrylamide; B, Bio-Rad's electrophoresis-purity acrylamide; control # 25281.

Figure 1 shows a UV profile of chemical polymerization for 2 samples of acrylamide polymerized under identical conditions in a quartz cuvette. Sample A was an "enzyme grade" acrylamide with a conductivity (50% w/w) of 3.75 μ S. Sample B was Bio-Rad's electrophoresis-purity acrylamide with a conductivity of 0.56 μ S. As the figure shows, polymerization is largely complete after about 90 min, even though the reaction proceeds to a small extent beyond that time. While sample A began to polymerize faster, sample B polymerized more completely, as indicated by the lower final UV absorbance.

Contaminants in acrylamide may be accelerators or inhibitors of polymerization. Therefore, initiation of polymerization, as indicated by reduced absorbance, may be faster with crude acrylamide than with highly refined acrylamide. However, the most important consideration is the completeness of polymerization. Polymerization of highly refined

acrylamide may be initiated more slowly, but conversion of monomer to polymer, as indicated by the low final absorbance, is more complete. Therefore, less residual monomer remains. Complete polymerization is critical for reproducibility in gel porosity.

Gel Exclusion Limit Determination

Estimation of protein molecular weight by SDS-PAGE is a widely employed procedure. The relative mobility of a protein in an SDS-PAGE gel is related to its molecular weight. A standard curve is constructed with proteins of known molecular weight by plotting the logarithms of their molecular weights versus the relative mobilities of the proteins. The relative mobility of a protein of unknown molecular weight is then fitted to the curve to determine its molecular weight.

A standard curve can be extrapolated to give the y-intercept, which represents the molecular weight exclusion limit of that particular gel. That is, proteins with a molecular weight greater than the y-intercept value will show zero mobility and will be excluded from the gel matrix.

Poorly polymerized gels have greater porosity due to incomplete chain elongation and crosslinking. As a result, the exclusion limit will be greater than for a well-polymerized gel of the same percent acrylamide. Furthermore, when polymerization is incomplete, exclusion limits are irreproducible. Use of highly purified gel-forming reagents and proper polymerization technique will result in the lowest and most reproducible exclusion limits for a given percent total monomer.

Figure 2 shows a typical curve obtained by plotting log molecular weight versus relative mobility following SDS-PAGE for a group of standard proteins. The antilog of the y-intercept value of this plot is 115,000 as determined by linear regression analysis. The approximate molecular weight exclusion limit of the gel is thus 115,000. The y-intercept value should be considered approximate because it depends upon the relative mobility of the proteins used as standards.

Although the y-intercept value will be different for every gel acrylamide percentage, and slightly different for every set of standards, the value should be highly reproducible from gel to gel if the same acrylamide percentage and standards are used. Thus, monitoring the y-intercept of the log molecular weight vs. relative mobility plot is an excellent assessment of reproducibility in polymerization technique.

* %C = (grams crosslinker x 100)/(grams monomer + grams crosslinker)




Fig. 2. A representative calibration curve for molecular mass (M_r) estimation. In the run that is plotted here (solid line), Bio-Rad SDS-PAGE standards with M_r of 200, 116.2, 97.4, 66.2, 45, 31, 21.5, 14.4, and 6.5 kD (closed circles, left to right) were separated on a 15% T SDS-PAGE gel. The plot shows the inherent nonlinearity of such curves. The straight-line segment in the middle of the plot is the most accurate range for M_r estimation. Larger polypeptides experience greater sieving than do those in the middle range, so the corresponding upper part of the curve has a different slope than in the middle. The curve in the smaller polypeptide range also deviates from a straight line because of less sieving. Because the scale is logarithmic, an estimate of M_r from a "best fit" straight line (dashed) is acceptable for many purposes.

Handling of Acrylamide

Use good laboratory practices, work in a well ventilated area and wear proper personnel protective equipment. Refer to the MSDS for further information.

Reagent Storage and Shelf Life

Acrylamide and bis-acrylamide — Electrophoresis-purity acrylamide and bis can be stored dry at room temperature (23–25°C) for at least 1 year.

Ammonium persulfate and potassium persulfate — These initiators can be stored tightly sealed at room temperature

for at least 1 year. Solutions should be made fresh daily, since persulfate in solution decomposes rapidly. Persulfate is a strong oxidizing agent. Disposal should be in accordance with local regulations.

TEMED --- This initiator can be stored tightly closed either at 4°C or at room temperature for at least 6 months.

After 10 to 12 months, a significant reduction in reactivity requires an increase in the concentration required for proper polymerization. This loss of reactivity is probably due, at least in part, to the gradual accumulation of water.

Riboflavin and riboflavin-5'-phosphate --- These photoinitiators can be stored dry at room temperature for at least 1 year. In aqueous solution, they are stable for at least 1 month if kept in the dark at 4°C. Riboflavin phosphate is usually preferred because of its greater solubility.

Polymerization Artifacts and Troubleshooting

Complete and reproducible polymerization is dependent on proper technique and pure gel-forming reagents. The table below lists commonly observed polymerization artifacts and problems, along with their probable causes and solutions.

Problem	Cause	Remedy	Problem	Cause	Remedy
SDS gel doesn't polymerize	<ul style="list-style-type: none"> Too little or too much APS or TEMED Failure to degas Temperature too low 	<ul style="list-style-type: none"> Requires 0.05% APS and 0.05% TEMED Degas 10–15 min Cast at room temperature, warming glass plates if necessary Use electrophoresis-purity reagents Make solution fresh daily 	Gel feels soft	<ul style="list-style-type: none"> Low % T Poor-quality acrylamide or bis Too little crosslinker bis concentration too high Crosslinker too high 	<ul style="list-style-type: none"> No remedy Use electrophoresis-purity reagents Make sure of proper %C Recheck solutions or weights Recheck %C
Swirls in gel	<ul style="list-style-type: none"> Poor-quality acrylamide or bis APS not freshly made Excessive catalysis — gel polymerized in <10 min Gel inhibition — polymerization time >1 hr Basic gradient; gel polymerization problem 	<ul style="list-style-type: none"> Reduce APS and TEMED by 25% each Increase APS and TEMED by 50%; degas Requires 0.015% APS, 1 µl/ml TEMED and 0.005% riboflavin Degas 1–2 min O₂ required for this reaction to initiate — don't degas Requires 0.015% APS, 1 µl/ml TEMED Degas 10–15 min at room temperature 	Gel brittle	<ul style="list-style-type: none"> Poor-quality acrylamide or bis incomplete catalysis Sample not equilibrated Excessive TEMED or APS SDS or sample buffer too old Gel temperature high 	<ul style="list-style-type: none"> Use electrophoresis-purity reagents Equilibrate sample to running conditions Reduce initiator concentrations by 25% Prepare fresh solutions Cool during run or run more slowly
IEF gel doesn't polymerize	<ul style="list-style-type: none"> Gel has no structure Riboflavin-catalyzed; gel was degassed too long APS alone doesn't polymerize Didn't degas for chemical polymerization; temperature too low 	<ul style="list-style-type: none"> Requires 0.015% APS, 1 µl/ml TEMED Degas 10–15 min at room temperature 	Inconsistent relative mobilities	<ul style="list-style-type: none"> Incomplete catalysis; excessive TEMED or APS Did not degas Acrylic acid contamination in acrylamide and bis 	<ul style="list-style-type: none"> TEMED and APS should be 0.05% Degas 10–15 min Use electrophoresis-purity reagents
Long polymerization time, incomplete catalysis	<ul style="list-style-type: none"> Poor-quality acrylamide or bis APS not freshly made Failure to degas Too little APS or TEMED Temperature too low Poor-quality acryl- 	<ul style="list-style-type: none"> Use electrophoresis-purity acrylamide and bis Make fresh APS Degas 10–15 min Increase both to 0.05% Cast at room temperature Use electrophoresis- 	High silver-staining background	<ul style="list-style-type: none"> Acrylic acid contamination in acrylamide and bis Acrylic acid contamination in acrylamide and bis Gel not aged long enough after photopolymerization 	<ul style="list-style-type: none"> Use electrophoresis-purity reagents Allow polymerization for 8 hr before using the gel
			Severe cathodic drift in IEF, molecules diffuse or don't reach proper pI	<ul style="list-style-type: none"> Poor-quality urea 	<ul style="list-style-type: none"> Deionize urea; use electrophoresis-purity reagents

Allison JH *et al.*, Effect of N,N,N',N'-tetramethylethylenediamine on the migration of proteins in SDS polyacrylamide gels, *Anal Biochem* 58, 592-601 (1974)

- * Triton is a trademark of Union Carbide Chemicals and Plastics Technology Corp.

[back to top](#)

- [Read more articles](#)
- [Read more Technical Articles from Bio-Rad](#)

Bio-Rad Contact Information ([More information about Bio-Rad](#))

Bio-Rad

Bio-Rad Laboratories, Inc.
Life Science Research Group
2000 Alfred Nobel Drive
Hercules, CA 94547
USA

Customer Service: 800-424 6723

Fax Number: 800-879 2289

Web Site: <http://discover.bio-rad.com>

[More information about Bio-Rad](#)

BIO-RAD

[Antibodies](#) | [Chromatography and Columns](#) | [Vectors](#) | [CPG & Phosphoramidites](#) | [Biomolecules](#) | [Assay Kits](#) | [Gene-Specific Product Directory](#)

[Specialized Search Tools](#)

[Join Life Science Community Discussion Forums](#)

[Hot Topics](#) | [DNA](#) | [RNA](#) | [Protein](#) | [Immunocytochemistry](#) | [Tissue Culture](#)

[Molecular Biology](#) | [Lab Equipment](#) | [Tissue Culture](#) | [Cell Biology](#) | [Bio Services](#) | [Protein Biochemistry](#)
[Immunochromatography](#) | [Antibody Search](#) | [Browse Antibodies](#) | [Software](#) | [Microarrays](#)

[Product Reviews](#) | [News](#) | [Protocols](#) | [New Technology](#) | [Product Centers](#) | [Promotions](#) | [Videos](#) | [Resources](#) | [Articles](#) | [Newsletter Sign-up](#) | [RSS](#)

[VISIT OUR SISTER SITES](#)

[Searching for medical products? Visit MedCompare.com](#) | [Searching for dental products? Visit DentalCompare.com](#)

Copyright© 1999 - 2007 BioCompare, Inc. All rights reserved

[About BioCompare](#) | [Contact Us](#) | [Help](#) | [Privacy Policy](#) | [Disclaimer & Terms of Use](#)

EXHIBIT 1

Entry printed from *Oxford English Dictionary Online*

Copyright © Oxford University Press 2008

sequence, n.

SECOND EDITION 1989

(ˈsiːkwəns) Also 4-6 **sequens**. [ad. late L. *sequentia*, f. *sequent-*em, pres. pple. of *sequi* to follow: see **SEQUENT** *a.* and **-ENCE**. Cf. OF. *sequence* (13th c. in Hatz.-Darm.), F. *séquence*, Sp. *secuencia*, Pg. *sequencia*, It. *sequenza*.

Orig. introduced (perh. through OF.) in the eccl. Latin sense (7 below). In this use *sequentia* was a transl. of eccl. Gr. ἀκολουθία, which denoted a neume or prolonged succession of notes sung on the last syllable of the Alleluia. When the Alleluia was adopted in the Western ritual, this neume was retained, but it became usual to sing it to a separate form of words, to which the name *sequentia* was transferred.

In its primary use the word first appears late in the 16th c.]

I. Succession, following.

1. a. The fact of following after or succeeding; the following of one thing after another in succession; an instance of this.

1593 SHAKES. *Rich. II.* II. i. 199 For how art thou a King But by faire sequence and succession? **1605** BACON *Adv. Learn.* I. ii. §2 For as in Man, the ripenesse of strength of the bodie and minde commeth much about an age.; So in States, Armes and Learning..haue a concurrence or nere sequence in times. **1644** BULWER *Chirol.* 138 The ancient form of absolution..may be also exhibited by one Hand laid in sequence of the other; or both conjoynd and held above the head. **a1656** BP. HALL *Serm.* Ps. cviii. 34 Wks. 1808 V. 240 What should I instance in that, whereof..the whole world is full: the inevitable sequences of sin and punishment? **1833** CHALMERS *Const. Man* (1835) II. II. i. 143 The constancy of nature's Sequences. **1843** GROVE *Corr. Phys. Forces* (1846) 6 If..we regard causation as invariable sequence, we can find no case in which a given antecedent is the only antecedent to a given sequent. **1843** MILL *Logic* I. v. §6. 139 Instead of Coexistence and Sequence, we shall sometimes say, for greater particularity, Order in Place, and Order in Time. **1862** SPENCER *First Princ.* II. iii. §47 (1867) 163 Relations of which the terms are not reversible become recognized as sequences proper; while relations of which the terms occur indifferently in both directions, become recognized as co-existences. **1866** G. MACDONALD *Ann. Q. Neighb.* xvi. (1878) 330 Now I must report another occurrence in regular

sequence. **1884** [LAURIE] *Metaph. Nova & Vet.* 115 There are fixed in his associative memory certain sequences as always occurring.

†**b. in sequence of:** in pursuance or consequence of. *Obs.*

a1648 LD. HERBERT *Hen. VIII* (1649) 262 The Cardinall..having read them, deliver'd immediatly the Great Seale; In sequence thereof, also submitting himself to the King. *Ibid.* 378 In sequence whereof, on the twelfth of March following..the Bishop..returned the Protestants this answer. *Ibid.* 394 France, where in sequence of a Protestation..to attend the French King..he resolved to march.

c. in sequence: one after another.

1575 GASCOIGNE *Posies, Weeds* (1907) I. 463 Davids salutacions to Berzabe wherein are three sonets in sequence, written uppon this occation. **1588** SHAKES. *Tit. A.* IV. i. 37 *Ti.* Why lifts she vp her armes in sequence thus? *Mar.* I thinke she meanes that ther was more than one Confederate in the fact. **1638** R. BAKER tr. *Balzac's Lett.* (vol. II.) 113 Fortune hath robbed me of it, for feare I should..have two pleasures in sequence. **1823** SOUTHEY *Hist. Penins. War* I. 20 The others were to be called upon in sequence. **1824** LANDOR *Imag. Conv., Johnson & Horne Tooke Wks.* 1853 I. 160/2 You will wonder at finding both a hexameter and pentameter, and in sequence.

2. a. Order of succession.

1586 A. DAY *Eng. Secretary* II. (1595) 4 Whereof the first in sequence which I will deliuer vnto you..shall be in the state coniecturall. **1607** SHAKES. *Timon* V. i. 211 Tell Athens, in the sequence of degree, From high to low throughout. **a1631** DONNE *Lett.* (1651) 60, I doubt..not that I writing in my dungeon of Michim without dating, have made the Chronologie and sequence of my Letters perplexed to you. **1657** SPARROW *Bk. Com. Prayer* (1661) 111 Wherein without any consideration of the sequence of time..the holy Doctrine, Deeds and Miracles of our Lord are the chief matters of our meditations. **1833** C. A. BOWLES in Southey *Corr.* (1881) 277 Admiration, disappointment, and disgust has been, I think, the sequence of feeling with which I have read them. **1862** STANLEY *Jew. Ch.* (1877) I. xix. 364 Works..arranged in chronological sequence. **1867** W. W. SMYTH *Coal & Coal-mining* 20 The annexed table exhibits the natural sequence where all the strata are developed. **1873** SPENCER *Stud. Sociol.* ii. 45 He asserts that there is a natural sequence among social actions. **1875** FORTNUM *Maiolica* iii. 24 The next example,

two years later, in sequence of date.

b. Gram. Chiefly in **sequence of tenses**, the manner in which the tense of a subordinate clause depends on that of the principal clause. Cf. CONSECUTION 2b.

1848 J. T. WHITE *Xenophon's Anab.* I. viii. §15 (1872) Notes 72 What is in Latin the sequence of tenses is in Greek the sequence of moods. **1891** SONNENSCHNEIDER *Plautus' Rudens* 91 The sequence of tenses *hic dico..qui adornaret ut faciat* is Plautine. **1892** L. KELLNER *Hist. Outl. Eng. Syntax* §371 Sequence of Tenses ('consecutio temporum'). Principal tenses depend on principal tenses; historical on historical.

c. Biochem. The order of the constituent nucleotides in a nucleic acid molecule or of the amino-acids in a polypeptide or protein molecule.

1959 *Arch. Biochem. & Biophysics* LXXXV. 290 The sequence of these trinucleotides was determined by digestion with semen monoesterase followed by snake venom diesterase with the resulting formation of a purine nucleoside, a purine nucleotide (Pu), and a pyrimidine nucleotide (Py). **1965** *Science* 19 Mar. 1462/1 During protein synthesis, the amino acid sequence of the polypeptide chain is determined by the interaction of a messenger RNA with transfer RNA's specific for a given amino acid. **1970** *Biochem. J.* CXVIII. 831/1 The recent determination of partial sequences at the cohesive ends of DNA from bacteriophage λ ..is an excellent example of the application of repair reactions with DNA polymerase..to nucleotide sequence studies. **1977** *Sci. Amer.* Dec. 55/1 The complete nucleotide sequence of the DNA of a small bacterial virus, ϕ X174, has been established.

3. a. A continuous or connected series (of things).

In 16th c. examples there is sometimes an allusion to the specific sense 4.

1575 GASCOIGNE *Posies, Flowers* (1907) I. 85 Of such our patrone here, The viscont Mountacute, Hath many comely sequences, well sorted all in sute. *Ibid.*, *Weeds* I. 463 In the beginning of the booke [he] wrote this sequence. **1589** *Pappe w. Hatchet* Elij, I haue manie sequences of Saints. **1605** BACON *Adv. Learn.* I. vii. §8. 35b, In this sequence of sixe Princes, we doe see the blessed effects of Learning in soueraigntie. **1616** I. T. A,B,C, *of Armes* C4, A perfect File is a sequence of men standing one behinde another. **1656** BLOUNT *Glossogr.*, *Sequences*, answering Verses, or Verses that answer one another sequentially; [1661 adds] things that follow one another in order. **1668** R. LASSELS *Voy. Italy* (1670) II. 183

EXHIBIT 2



All Databases

Enter Text Here

Reset
Advanced

Help

General Help

Formats

Gaps

Matrix

References

ClustalW2 Help

ClustalW2 FAQ

Jalview Help

Scores Table

Alignment

Guide Tree

Colours

ClustalW2 Results

Results of search	
Number of sequences	2
Alignment score	39
Sequence format	Pearson
Sequence type	nt
JalView	Start Jalview
Output file	clustalw2-20090109-16515619.output
Alignment file	clustalw2-20090109-16515619.aln
Guide tree file	clustalw2-20090109-16515619.dnd
Your input file	clustalw2-20090109-16515619.input

To save a result file right-click the file link in the above table and choose "Save Target As".
If you cannot see the JalView button, reload the page and check your browser settings to enable Java Applet.

Scores Table

SeqA Name	Len(nt)	SeqB Name	Len(nt)	Score
1 Seq1	10	2 Seq2	10	90

PLEASE NOTE: Some scores may be missing from the above table if the alignment was done using multiple

Alignment

CLUSTAL 2.0.10 multiple sequence alignment

```
Seq1      ATTCTTGTTA- 10
Seq2      -TTCTTGTTAA 10
          *****
```

PLEASE NOTE: Showing colors on large alignments is slow.

[Show Colors](#)[View Alignment File](#)

Guide Tree

[Show as Phylogram Tree](#)[Show Distances](#)[View DND File](#)

(Seq1:0.05,Seq2:0.05) ;

Cladogram

[Show as Phylogram Tree](#)[Show Distances](#)[View DND File](#)

Right-click on the above tree to see display options.

Problems printing? Read [how to print a Phylogram or Cladogram](#).